To sum up, ANRIL is highly expressed in the serum of patients with CHD and it can be used as an effective biomarker for evaluating the therapeutic effect on the disease and the 3-year overall survival rate of the patients. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.